Less than 10% of individuals that would benefit from obesity jabs like Wegovy have access to them, states the World Health Organization as it issues its initial advice on the therapies.
Given more than one billion people worldwide currently obese, it is urging increased and just availability to these injectable treatments.
Per forecasts, more than two billion will be living with obesity by 2030 if no action is taken.
"Our latest guidelines affirms that excess weight is a chronic disease that can be treated with thorough and continuous treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are major obstacles to broad availability to the treatments that can help people shift considerable weight, explains the body.
Skinny Jab Supply Crisis
Despite the present best projected case, the production of such drugs would only suffice for approximately 100 million people – fewer than 10% of the global need, per the health organization.
The recommendation calls on countries and companies to expand availability, via strategies including voluntary licensing.
A patent on semaglutide – the main component of Novo Nordisk's Wegovy – is due to expire in multiple nations in 2026.
How Obesity Drugs Work
The injections imitate a biological compound to slow digestion, suppress the appetite and increase satiety so people eat less.
Individuals typically begin shedding pounds after several weeks of commencing the weekly injections.
Evidence suggests users may regain a significant portion a year later of halting the drug, when their normal food cravings come back.
Being carrying excess weight increases your risk for experiencing medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight affects people in every country and was linked to over three and a half million deaths worldwide in 2024, according to the WHO.
